12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ampligen rintatolimod: Phase I/II started

Hemispherx began a double-blind, placebo-controlled, U.S. Phase I/II to compare nasal adjuvant Ampligen plus Flumist vs. Flumist alone in 72 healthy volunteers. MedImmune LLC, a subsidiary...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >